OTC · IMVIF
IMV Inc.
$0.00$0.00 (0.0%)
IMV Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
Loading market information…
OTC · DMKPQ · USD
Stock price, earnings
Quote as of Nov 10, 2025, 09:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
DMK Pharmaceuticals Corporation’s quoted price sits in the lower half of its reported 52-week range, 90.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow DMK Pharmaceuticals Corporation’s reporting calendar.
THE COMPANY BEHIND THE TICKER
DMK Pharmaceuticals Corporation functions as a clinical-stage neuro-biotechnology company, focusing on the development and market introduction of therapeutic solutions across several medical fields, including allergies, opioid overdose, respiratory conditions, and inflammatory diseases. Its primary product candidate currently in clinical trials is DPI-125, designed for the treatment of opioid use disorder. The company's portfolio also encompasses SYMJEPI, an epinephrine injection used for the immediate management of severe allergic reactions (anaphylaxis) triggered by factors such as insect stings, foods, medications, or those that are idiopathic or exercise-induced. Additionally, they offer ZIMHI, a naloxone injection vital for reversing opioid overdoses. The organization, previously named Adamis Pharmaceuticals Corporation, officially rebranded to DMK Pharmaceuticals Corporation in September 2023. Headquartered in San Diego, California, DMK Pharmaceuticals Corporation, along with its associated entities, filed for voluntary Chapter 11 bankruptcy reorganization in the U.S. Bankruptcy Court for the District of Delaware on February 2, 2024.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:46 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Sep 29, 2021 |
| -$5.81 |
| $759.96K |
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$0.00$0.00 (0.0%)
IMV Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00$0.00 (0.0%)
BIMI International Medical Inc.’s quoted price sits in the lower half of its reported 52-week range, 80.0% below the high.
$0.00$0.00 (0.0%)
Millennium Sustainable Ventures Corp.’s quoted price sits in the lower half of its reported 52-week range, 75.0% below the high.
$0.00$0.00 (0.0%)
American Medical Technologies Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00-$0.00 (0.0%)
Omnimmune Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 0.0% below the high.
$0.00$0.00 (0.0%)
eFFECTOR Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.0% below the high.
$0.00$0.00 (0.0%)
BioELife Corp.’s quoted price sits in the lower half of its reported 52-week range, 66.67% below the high.
$0.00$0.00 (0.0%)
HLK Biotech Holding Group, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.46% below the high.
